Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Neurology · Multiple Sclerosis

Understanding Your Diagnosis: From PRMS to Modern Terminology

At a Glance

Progressive relapsing MS (PRMS) is an older classification. Doctors now identify whether MS is primary progressive or secondary progressive and separately describe activity, such as relapses or new MRI lesions, and sustained progression.

Navigating a Multiple Sclerosis (MS) diagnosis is challenging, especially when the words doctors use seem to change. If you have seen the term Progressive Relapsing MS (PRMS) in your records or online, you may be confused to find it is no longer used by most specialists today. In 2013, international experts updated the way MS is classified to better reflect how the disease actually behaves and to help doctors choose the most effective treatments [1][2].

Why the Terminology Changed

In the past, MS was often put into rigid boxes. Progressive Relapsing MS (PRMS) was once used to describe people who had a steady worsening of symptoms from the very beginning but also experienced occasional sudden attacks, known as relapses [3].

The 2013 updates, known as the Lublin classification, retired PRMS because researchers realized that “relapsing” and “progressive” are not two different diseases, but rather two different things happening at the same time [2][4]. Instead of a separate category, doctors now use “qualifiers” to describe your specific MS at this moment:

  • The Underlying Course: Is it Primary Progressive (PPMS) or Secondary Progressive (SPMS)? [1]
  • Activity: Is there evidence of new inflammation (relapses or new spots on an MRI)? [4]
  • Progression: Is the level of disability steadily increasing over time, independent of relapses? [5]

These qualifiers can change. You might be “active” this year, and “not active” in five years.

Defining the Modern Categories

If you were previously told you had PRMS, your diagnosis will now likely fall into one of two categories, depending on how your MS first started:

  • Primary Progressive MS (PPMS): This describes people whose symptoms have gradually worsened from their very first MS symptom [3][6]. In large studies, a portion of people with PPMS—often estimated around 25% over a given observation period—may show “activity” (relapses or new MRI lesions) at different points in their disease [7].
  • Secondary Progressive MS (SPMS): This is diagnosed when a person started with Relapsing-Remitting MS (RRMS)—a phase of clear attacks followed by recovery—but later transitioned into a phase where disability worsens steadily [3][8]. If this progression is currently accompanied by relapses or new MRI activity, it is called Active SPMS.

Activity vs. Progression: What They Mean for You

The most important shift in modern terminology is the distinction between activity and progression. These terms describe two different processes:

Term What it Means How it is Found
Activity Focal inflammation, or “new” damage. This is often what MS medications are best at targeting [9]. Found through clinical relapses (sudden new symptoms lasting >24 hours without fever) or new/enlarging spots on an MRI [4].
Progression The gradual accumulation of disability over time [10]. Found by comparing physical exams (like the EDSS scale) over 3 to 6 months to confirm a meaningful decline [5][11].

A person can be “active but not progressing” (having relapses but staying stable in between) or “progressing but not active” (getting worse gradually without any new MRI spots or attacks) [12][7]. Understanding which of these you are experiencing helps your care team decide if a specific disease-modifying therapy (DMT) is likely to help [11].

Common Misunderstandings

It is a common mistake to think that having a relapse automatically means you have “Relapsing MS” and not “Progressive MS.” In reality, many people with progressive forms of the disease still have inflammatory activity [13].

Another misunderstanding is that a single bad day, or even a single slightly worse exam, means you are “progressing.” True progression requires confirmed, sustained worsening over time [10]. While the names have changed, the goal remains the same: identifying exactly what is happening in your nervous system to provide the most targeted care possible.

Common questions in this guide

Is PRMS still used as a diagnosis?
PRMS is an older term that most specialists no longer use as a separate MS category. Doctors now describe the underlying course as PPMS or SPMS and separately record whether the disease is active or progressing.
How can I tell whether my MS is PPMS or SPMS?
PPMS means symptoms gradually worsened from the first MS symptoms. SPMS follows an earlier relapsing-remitting period in which attacks were followed by recovery, followed later by steady disability worsening.
What does an active MS diagnosis mean?
Active MS means there is evidence of recent inflammatory activity, such as a clinical relapse or a new or enlarging lesion on MRI. Activity can occur whether or not disability is also steadily worsening.
How do doctors decide whether MS is progressing?
Progression means a sustained increase in disability over time that is not explained only by a relapse. Clinicians compare physical examinations over several months, sometimes using a standardized disability scale, to confirm meaningful worsening.
Can progressive MS include relapses?
Yes. People with progressive MS can still have inflammatory activity, including relapses or new MRI lesions. This is why a progressive course may also be described as active.
Why do older records call my MS PRMS?
PRMS was used before the 2013 update to MS classification for people whose disease worsened from the beginning but also included relapses. Current terminology separates the underlying course from activity and progression, so newer records may use PPMS or SPMS instead.
Can activity or progression change my treatment?
Relapses and new MRI lesions may show activity that could respond to a disease-modifying therapy, while progression describes disability that accumulates over time. Your neurologist uses these findings, along with your history and examination, to discuss treatment options.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my history of symptoms, do I have primary progressive MS (PPMS) or secondary progressive MS (SPMS)?
  2. 2.What evidence from my MRI or physical exams shows 'activity' versus 'progression'?
  3. 3.Was there a distinct relapsing-remitting phase in my history before the progression began?
  4. 4.How does the presence of activity—like new lesions or relapses—change the treatment options you are considering for me?
  5. 5.Can you explain why my diagnosis might have been listed differently in older records compared to today?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Toward Precision Phenotyping of Multiple Sclerosis.

    Pitt D, Lo CH, Gauthier SA, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2022; (9(6)) doi:10.1212/NXI.0000000000200025.

    PMID: 36041861
  2. 2

    The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.

    Sorensen PS, Sellebjerg F, Hartung HP, et al.

    Brain : a journal of neurology 2020; (143(9)):2637-2652 doi:10.1093/brain/awaa145.

    PMID: 32710096
  3. 3

    Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.

    Jia X, Madireddy L, Caillier S, et al.

    Annals of neurology 2018; (84(1)):51-63 doi:10.1002/ana.25263.

    PMID: 29908077
  4. 4

    Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis.

    Blok KM, van Rosmalen J, Tebayna N, et al.

    Frontiers in neurology 2023; (14()):1277477 doi:10.3389/fneur.2023.1277477.

    PMID: 38020591
  5. 5

    No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

    Havrdová E, Arnold DL, Bar-Or A, et al.

    Multiple sclerosis journal - experimental, translational and clinical 2018; (4(1)):2055217318760642 doi:10.1177/2055217318760642.

    PMID: 29568544
  6. 6

    Progressive Multiple Sclerosis.

    Amezcua L

    Continuum (Minneapolis, Minn.) 2022; (28(4)):1083-1103 doi:10.1212/CON.0000000000001157.

    PMID: 35938658
  7. 7

    Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study).

    Pérez-Miralles F, Prefasi D, García-Merino A, et al.

    Multiple sclerosis and related disorders 2021; (50()):102860 doi:10.1016/j.msard.2021.102860.

    PMID: 33647591
  8. 8

    Secondary Progressive Multiple Sclerosis: Definition and Measurement.

    Plantone D, De Angelis F, Doshi A, Chataway J

    CNS drugs 2016; (30(6)):517-26 doi:10.1007/s40263-016-0340-9.

    PMID: 27166830
  9. 9

    Diagnosis and Treatment of Multiple Sclerosis: A Review.

    McGinley MP, Goldschmidt CH, Rae-Grant AD

    JAMA 2021; (325(8)):765-779 doi:10.1001/jama.2020.26858.

    PMID: 33620411
  10. 10

    Chronic lesion activity and disability progression in secondary progressive multiple sclerosis.

    Beynon V, George IC, Elliott C, et al.

    BMJ neurology open 2022; (4(1)):e000240 doi:10.1136/bmjno-2021-000240.

    PMID: 35720980
  11. 11

    Risk of secondary progressive multiple sclerosis after early worsening of disability.

    Dzau W, Sharmin S, Patti F, et al.

    Journal of neurology, neurosurgery, and psychiatry 2023; (94(12)):984-991 doi:10.1136/jnnp-2023-331748.

    PMID: 37414538
  12. 12

    Disability accrual in primary and secondary progressive multiple sclerosis.

    Harding-Forrester S, Roos I, Nguyen AL, et al.

    Journal of neurology, neurosurgery, and psychiatry 2023; (94(9)):707-717 doi:10.1136/jnnp-2022-330726.

    PMID: 37068931
  13. 13

    Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.

    Leppert D, Kropshofer H, Häring DA, et al.

    Neurology 2022; (98(21)):e2120-e2131 doi:10.1212/WNL.0000000000200258.

    PMID: 35379762

This page is for informational purposes only and does not constitute medical advice. A neurologist should interpret your MS history, MRI findings, and examination when updating the diagnosis and discussing treatment.

Get notified when new evidence is published on progressive relapsing multiple sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.